Personalized Medicine: A Primer on the Role of Pharmacogenetics and Pharmacogenomics in Oncology
Download our white paper Personalized Medicine: A Primer on the Role of Pharmacogenetics and Pharmacogenomics in Oncology. Adverse drug reactions (ADRs) are the fourth leading cause of death in the United States. Following the Human Genome Project and the International HapMap Project, scientist and physicians now understand how variations in human and tumor genetics can guide the development of treatment targets and new drugs. Pharmacogenetics and pharmacogenomics have evolved from these advances impacting the development of screening tools, diagnostics, and targeted therapies.
Recent Advances in Pharmacogenetics and Pharmacogenomics:
- Molecular targeting in drug development
- Diagnosis and screening
- Treatment and benefits/risk analysis
In this white paper UBC’s Don Gabriel, MD, PhD and Judy Lytle, PhD, MBEE, PMP discuss personalized medicine, applications of pharmacogenetics/pharmacogenomics in oncology and the positive impact they have on drug development.
Get started by completing the form to access our white paper Personalized Medicine: A Primer on the Role of Pharmacogenetics and Pharmacogenomics in Oncology.
Want to know more about us?
Subscribe Now
Want to know more about us?
Subscribe Now
Providers
Thank You for Connecting with UBC
Lorem ipsum dolor sit amet consectetur. Mi proin enim ipsum nascetur. Venenatis odio scelerisque non netus ac et pellentesque.
What You Can Expect Next
Lorem ipsum dolor sit amet consectetur. Cras aliquam erat eget magna sollicitudin.
- Leverage automation to move fast
- Always give customers a human to chat to
- Automate customer support and close leads faster
Get Ready to Change Your Business
Lorem ipsum dolor sit amet consectetur. Mi proin enim ipsum nascetur. Venenatis odio scelerisque non netus ac et pellentesque.
Service Request
Bekki Bracken Brown
President & Chief Executive Officer
Bekki Bracken Brown serves as the President and CEO of UBC, guiding the company’s mission and values, including the improvement of access for patients to receive better outcomes. She oversees all aspects of UBC, such as operations, business growth strategy, sales and marketing, and acquisition support.
With over 20 years of industry experience, Ms. Brown brings knowledge from a successful career in senior management from her tenure at Quintiles, INC Research, and, most recently, with Syneos Health. She’s been a member of the North Carolina BIO Board of Directors since 2019. She is also a member of the Healthcare Businesswomen’s Association — Southeast Chapter and CHIEF, an organization that supports women executive leaders. Ms. Brown earned her bachelor’s degree at Duke University.